Zai Lab Limited ZLAB
26.42 USD -0.01 (-0.04%)
At closeNov 11, 2026, 5:18 PM EST
26.85 +0.43 +1.63%
After hours · Nov 11, 5:18 PM ET
25.33 Day range 26.50
15.96 52-week range 29.02
- YTD
- +49.77%
- 1 year
- +20.09%
News
zacks.com Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High? The consensus price target hints at a 40.2% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
marketbeat.com Zai Lab Q3 Earnings Call Highlights Zai Lab NASDAQ: ZLAB reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate…
seekingalpha.com Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
zacks.com Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Zai Lab Limited (ZLAB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key…
benzinga.com Zai Lab To Present Updated Data From Phase 1b/2 Trial Of Zocilurtatug Pelitecan Showing Clinically Meaningful, Durable Anti-Tumor Responses In Patients With Previously Treated Advanced Extrapulmonary Neuroendocrine Carcinomas At The North American Neuroendocrine Tumor Society Symposium In the Phase 1b/2 trial, zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, demonstrated clinically meaningful responses in patients with previously treated advanced…
benzinga.com Zai Lab Q3 2026 Earnings Call Transcript Zai Lab (NASDAQ:ZLAB) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
businesswire.com Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that updated data from a Phase 1b/2 trial of…
benzinga.com Zai Lab Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $108.208M Beat $105.825M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 33.33 percent. This is a 33.33 percent decrease over losses of $(0.03) per…
businesswire.com Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma, today announced financial results for the third quarter of 2026,…
seekingalpha.com Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer Transcript Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer Transcript
marketbeat.com Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study Zai Lab NASDAQ: ZLAB presented early-stage data at the 2026 European Society for Medical Oncology meeting for zoci, its DLL3-targeted antibody-drug conjugate, in combination with atezolizumab, with…
benzinga.com Zai Lab Announces Phase 1b Zoci Plus Atezolizumab Trial Delivers 81.8% Response Rate In First-Line Extensive-Stage Small Cell Lung Cancer, Advances Toward Phase 3 At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of…
businesswire.com Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from a global Phase 1b clinical…
businesswire.com Zai Lab Announces $250 Million Private Placement SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase…
businesswire.com Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2026 financial results and provide recent corporate…
defenseworld.net Zai Lab Limited Unsponsored ADR (ZLAB) – What Are Brokerages Thinking About This Stock? Shares of Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are covering the company,…
businesswire.com Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company's internally developed…
defenseworld.net Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey Zai Lab (NASDAQ: ZLAB - Get Free Report) and Janux Therapeutics (NASDAQ: JANX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies…
defenseworld.net Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK) Cytokinetics (NASDAQ: CYTK - Get Free Report) and Zai Lab (NASDAQ: ZLAB - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two…
benzinga.com Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript Zai Lab (NASDAQ:ZLAB) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time…
defenseworld.net Zai Lab (NASDAQ:ZLAB) Shares Climb 3.8% – Here’s Why Zai Lab Limited Unsponsored ADR (NASDAQ: ZLAB - Get Free Report) shot up 3.8% during mid-day trading on Monday. The company traded as high as $26.12 and last traded at $25.93. 164,998 shares were…
businesswire.com Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly…
benzinga.com The Insider Report: The Leaders Have Taken Off Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and…
fool.com Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
benzinga.com Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. futures rose, while Limoneira fell 8.4% after missing earnings and sales estimates. Resolution Minerals and Cooper led other premarket decliners.
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
cnbc.com Z.ai shares surge 8% after releasing new AI model running only on Chinese chips Z.ai's shares rose after the company launched a new AI model that it claimed runs only on Chinese chips. It's the latest indication of China's efforts to ramp up homegrown computing capability.
seekingalpha.com Zai Lab: Revenue Growth And Zoci's Upside Optionality ZLAB has grown from a Greater China licensing platform into a dual-engine biopharma. They have a growing proprietary global pipeline with KarXT and TIVDAK. And management expects product sales to…
benzinga.com Citigroup Maintains Buy on Zai Lab, Raises Price Target to $45 Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and raises the price target from $44 to $45.
benzinga.com Zai Lab Q2 EPS $(0.46) Misses $(0.06) Estimate, Sales $105.751M Beat $105.323M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.06) by 666.67 percent. This is a 24.32 percent decrease over losses of $(0.37)…- benzinga.com Zai Lab Says FDA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3 Antibody-Drug Conjugate, For Treatment Of Neuroendocrine Carcinomas - NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need- U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for…
- benzinga.com Zai Lab Announces EMA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3-Targeting Antibody-Drug Conjugate, For Treatment Of Pulmonary Neuroendocrine Carcinomas - European Medicines Agency's Committee for Orphan Medicinal Products recognized zoci's preliminary clinical data as suggestive of a clinically relevant advantage over currently authorized therapies…
benzinga.com UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Monday.
benzinga.com The FDA Grants Fast Track Designation To Zai Lab's Zocilurtatug Pelitecan (Zoci, formerly ZL-1310) for Extrapulmonary Neuroendocrine Carcinomas Following Progression After Standard First-Line Therapy Zai Lab reported promising preliminary data from an ongoing registration-enabling multicenter, Phase 1b/2 clinical trial of zoci (NCT06885281) in patients with epNEC and other selected solid tumors…- benzinga.com Citigroup Maintains Buy on Zai Lab, Lowers Price Target to $44 Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and lowers the price target from $47 to $44.
- benzinga.com Zai Lab Q1 EPS $(0.46) Beats $(0.54) Estimate, Sales $99.611M Miss $108.450M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.54) by 14.81 percent. This is a 2.22 percent decrease over losses of $(0.45) per…
- benzinga.com Zai Lab Announces Clinical Data Indicating Zoci, DLL3-Targeting ADC, Provides Rapid And Robust Intracranial Responses In Patients With Previously Treated ES-SCLC And Brain Metastases And Other NECs Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases;…
benzinga.com Boehringer Ingelheim, Zai Lab Collaborate Over Dual DLL3-Targeting Combination To Assess Safety, Tolerability Of Combining Obrixtamig, Boehringer Ingelheim's DLL3/CD3 T-Cell Engager Boehringer Ingelheim and Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The- benzinga.com Zai Lab and Amgen Team Up to Test New Combo Treatment for Lung Cancer Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ:AMGN) to evaluate Zai Lab's investigational delta-like ligand 3…
benzinga.com JP Morgan Maintains Overweight on Zai Lab, Lowers Price Target to $32 JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the price target from $39 to $32.- benzinga.com Zai Lab To Present Investigational Oncology Therapies To Be Presented Across Four Posters At American Association For Cancer Research Annual Meeting 2026 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company's internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming…
- benzinga.com Cantor Fitzgerald Maintains Overweight on Zai Lab, Lowers Price Target to $37 Cantor Fitzgerald analyst Li Watsek maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the price target from $55 to $37.
- benzinga.com CORRECTION: Zai Lab Q4 EPADS $(0.46) Misses $(0.05) Estimate, Sales $127.597M Beat $124.472M Estimate Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.05) by 838.78 percent. This is a 42.5 percent increase over losses of $(0.80)…
benzinga.com Zai Lab: Q4 Earnings Insights 
benzinga.com Zai Lab Q4 Earnings Summary & Key Takeaways 
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com An Overview of Zai Lab's Earnings - benzinga.com JP Morgan Maintains Overweight on Zai Lab, Lowers Price Target to $39 JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the price target from $46 to $39.
benzinga.com Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter 
benzinga.com Earnings Scheduled For November 6, 2025